These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31585959)

  • 1. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.
    Fürstenau M; Hallek M; Eichhorst B
    Haematologica; 2019 Nov; 104(11):2144-2154. PubMed ID: 31585959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
    Burger JA
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
    [No Abstract]   [Full Text] [Related]  

  • 5. The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?
    Jain N; OʼBrien S
    Cancer J; 2019; 25(6):374-377. PubMed ID: 31764117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?
    Ujjani C; Cheson BD
    Cancer J; 2019; 25(6):449-454. PubMed ID: 31764127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
    Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
    Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
    Voorhies BN; Stephens DM
    Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
    Vitale C; Ferrajoli A
    Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Wendtner CM
    Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolving Frontline Treatment in Chronic Lymphocytic Leukemia.
    Coutre SE
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):5-6. PubMed ID: 27168203
    [No Abstract]   [Full Text] [Related]  

  • 14. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we closer to a standard of care for Richter's syndrome? Novel treatments on the horizon.
    Pham N; Coombs CC; O'Brien S
    Expert Rev Hematol; 2024; 17(4-5):117-126. PubMed ID: 38693662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
    Cramer P; Langerbeins P; Hallek M
    Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.
    Sengar M; Jain H; Rajendra A; Rengaraj K; Thorat J
    Curr Hematol Malig Rep; 2020 Jun; 15(3):168-176. PubMed ID: 32542586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.